AcuraStem Awarded Target ALS Grant to Advance Therapeutics Targeting a Core Driver of ALS
PASADENA, Calif., March 10, 2026 /PRNewswire/ -- AcuraStem, a patient-based biotechnology company developing disease-modifying therapies for amyotrophic lateral sclerosis (ALS),...
Read moreDetails